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Abstract 
Glycoproteins are the underappreciated stars in the world of science. These proteins – 
specifically, membrane-bound glycoproteins – are known to have been difficult to study, for they 
present many hurdles: they are complex, hydrophobic, and are stable in only highly specific 
environments. However, investigations into their structure and function are paramount, for 
glycoproteins are essential in the biological world. Glycoproteins serve as enzymes and 
hormones, and aid in clotting and locomotion. While there have been several studies of 
membrane glycoproteins, most of these have focused on their unique attribute: their association 
with sugar groups. It has recently been shown that it is possible to use the enzyme N- 
glycosyltransferase to attach sugars to proteins providing a method for in vitro glycosylation (5). 
Using a membrane-mimetic environment, we are attempting to utilize these methods to 
glycosylate a truncated form of γ-Sarcoglycan (GSCGtm), a protein implicated in the disease 
etiology of Duchenne Muscular Dystrophy. These studies are aimed at shedding light on the 
effects of glycosylation on the structure and dynamics of GSCGtm, in order to provide 
information that can be used in future treatment modalities. For these studies, milligram amounts 
of pure protein are required. The work presented here highlights our successful efforts to 
recombinantly express and purify this membrane protein.  
 
Introduction 
 Membrane proteins are abundant within cell membranes. They serve, among many 
things, to provide a cell structure, as a channel for ions to pass through, and to trigger 
intracellular signaling pathways (3). Figure 1 depicts different representations of membrane 
proteins. However, given their importance, little is none about them, for they are hard to work 
 Gardner 3 
with. While it is possible to know which portion of a protein passes through the membrane 
thanks to the amino acid sequence, the folded three-dimensional structures of most membrane 
proteins have yet to be determined (1). These membrane proteins are often subjects of 
glycosylation, which occurs when a sugar is added to the protein (1). Figure 2 shows a 
membrane protein that has been glycosylated. Though these proteins prove difficult to work 
with, the goal of this project is to tackle the unknown and to determine the structure of the 
membrane-bound glycoprotein γ-Sarcoglycan (GSCG). To do so, we will obtain a purified 
sample of GSCG and determine its structure by nuclear magnetic resonance (NMR). 
 Sarcoglycan is a subunit of the Dystrophin glycoprotein complex. This complex is found 
in the plasma membrane of cells and plays a role in the stabilization of muscle cells (4). Figure 3 
represents the Dystrophin complex and shows the Sarcoglycan subunits. As shown, multiple 
forms of Sarcoglycan are found within the complex; when the Sarcoglycan subunits are absent, it 
can lead to a leaky plasma membrane. It has been found that muscular dystrophy can result from 
genetic mutations to genes encoding GSCG (4). Therefore, the importance of GSCG cannot be 
understated.  
 While the structure and exact role of GSCG is not known, many features of the protein 
are. The gene encoding GSCG is found on chromosome 13 and the protein is believed to play a 
role in stabilizing the plasma membrane of skeletal and cardiac muscles (4). Cardiomyopathy 
and muscular dystrophy can result from a recessive mutation of the gene encoding GSCG. The 
most common mutation is Δ521-T. This frameshift mutation leads to a stop codon, which 
produces a truncated, unstable protein (4). Determining the structure of GSCG, as well as 
observing the effects of glycosylation on the protein, will provide information on how to best 
treat those affected by this mutation.  
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The truncated version of GSCG I worked with, GSCGtm, is approximately 10kDa; this 
engineered protein contains the necessary glycosylation site, and also includes the 
transmembrane domain. Removing portions of the extracellular and intracellular domain will 
facilitate observing any change in the molecular weight once glycosylation is performed. This 
truncated version proved difficult to work with, leading to some issues within the purification 
process. The hope is to someday attach a sugar by in vitro glycosylation to the then purified 
GSCGtm. Following this glycosylation, additional NMR will be conducted, allowing one to see 
the changes in structure the added sugar entails.  
 
Methodology  
Four 1L growths of expression E. coli in either LB or 15N-labeled media are grown with 
the antibiotic carbenicillin from a starter and overnight growth. IPTG is later added for protein 
expression. To remove impurities, lysis is performed, utilizing three different buffers. The cells 
are sonicated and the cell lysis is centrifuged after administering Resuspension I and II buffers. 
The precipitate, containing the inclusion bodies, is dissolved in binding buffer made with the 
denaturant guanidine hydrochloride. The solubilized protein is dialyzed to remove the denaturant 
and associated lipids. Following this the protein is frozen and lyophilized. The target protein, 
GSCGtm, is expressed with a HIS6-TRPΔLE fusion sequence followed by a methionine residue 
that allows for the cleavage of the fusion protein from the target protein. Cleavage by cyanogen 
bromide is done by dissolving the protein in 70% formic acid and adding dry cyanogen bromide. 
After three hours, the cleavage solution is dialyzed to neutralize its pH. The dialyzed sample is 
then frozen and lyophilized. The cleaved product can further be separated by FPLC to isolate 
pure GSCGtm. These steps are depicted in Figure 4. 
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Alterations to Methodology 
As anticipated, this membrane-bound glycoprotein has been challenging to work with. 
Over the years we have approached it from a variety of different angles. To begin, we originally 
used high performance liquid chromatography (HPLC). After noticing HPLC was not providing 
great separation between peaks – which means we were not isolating GSCGtm – we decided to 
transition to fast purification liquid chromatography (FPLC). From there, we began to run our 
protein through two size exclusion columns in series, with the hope of furthering separating 
GSCGtm. These results proved promising, but were still not quite where we wanted them to be. 
Upon the addition of 100mmol NaCl to the running buffer, we noticed that our FPLC graph 
looked better, with improved peak separation. Currently, we use double FPLC columns, 
combined with 100mmol NaCl in the running buffer, to purify GSCGtm.  
While the changes to the FPLC protocol might be the most drastic, other small alterations 
have also occurred. Following lysis, we began to add the denaturant guanidine hydrochloride, in 
order to remove lipid impurities. This step has led to what we believe to be more pure GSCGtm. 
The most recent change in protocol, however, comes in the form of a nickel column. Because we 
believe our protein is aggregating early on in FPLC, we decided to try to purify our protein with 
an additional step. The six histidines found on our fusion sequence, HIS6-TRPΔLE, makes it 
possible for us to run a nickel column. This column binds only our protein, while other 
impurities within the solution are washed away. We can then collect pure GSCGtm. While we are 
hopeful with this approach, no results have yet been recorded, for it is a recently added step.  
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Results 
We were able to successfully express GSCGtm by recombinant methods using a fusion 
expression in E. coli for both unlabeled and 15N-labeled protein, as shown in Figure 5. The 
amino acid sequence, shown in Figure 6, was used to determine the transmembrane portion of 
GSCGtm. This transmembrane domain is illustrated by Figure 7. The protein was then purified 
using chemical cleavage and size exclusion FPLC. Our results indicate that GSCGtm
 
may be 
aggregating in the FPLC sample; the question remains how to best separate and purify GSCGtm. 
However, we were able to achieve better separation by FPLC when utilizing two columns in 
series and adding 100mmol NaCl to the running buffer. Figure 8 shows these results. The 
purified protein will then be used to conduct in vitro glycosylation in order to determine the 





The ability to breathe, sit, eat, or walk is commonly taken for granted by those who have 
fully functioning muscular systems. For those with muscular dystrophy, these thoughtless tasks 
are prevented due to muscle instability. In fact, by adolescence, many of those affected by 
muscular dystrophy will be wheelchair bound. To this date, there is no cure for muscular 
dystrophy, a disorder that affects roughly every 1 in 3500 males (6). However, it is known that 
the disorder is caused by mutations to proteins found within the dystrophin complex. By 
focusing my research on GSCGtm, I worked to establish beneficial information for those affected 
by muscular dystrophy. GSCG is a biologically important protein, one whose structures and 
dynamics will hopefully be determined through an extension of my research, as well as the 
effects of glycosylation on a truncated form of GSCG.  




Figure 1. Different forms of membrane proteins (2). GSCGtm most resembles the version labeled 
“1,” for it contains a single transmembrane domain.  
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Figure 2. Membrane protein that has been glycosylated, indicated by blue oligosaccharides (2). 





Figure 3. The Dystrophin complex. GSCG can be seen in orange and clearly represents a 
membrane protein. The complex is shown to be interacting with the sarcolemma of muscle cells.  
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Figure 4. Visual representation of the purification methodology of GSCGtm. 
 
 
Figure 5. Expression vector map for the GSCGtm construct. The DNA sequence of GSCGtm was 
inserted within the pHLV plasmid between the HinDIII and BamHI restriction sites. The His-
tagged TrpΔLE fusion partner is contained within the plasmid as well. For chemical cleavage, an 
N-terminal methionine and two C-terminal stop codons were added to the DNA insert. 
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Figure 6. Amino acid sequence of truncated GSCGtm. The glycosylation site, made up of the 
sequence NVT, is highlighted. Serine substitutions for cysteine and methionine residues are 




Figure 7. Kyte-Doolite hydropathy plot of GSCGtm. This plot shows that a transmembrane 
domain exists near the N-terminus of the protein and encompasses approximately 23 amino 
acids.  
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Figure 8. Fast purification liquid chromatography (FPLC) was used to purify the cleaved target 
protein, followed by an SDS-PAGE gel. Lanes 1-4 correspond to peaks at 16mL, 20mL, 23mL, 
and 29mL. The third lane corresponds with the size of TrpΔLE while the fourth lane contains a 
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